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Abstract 
 
Faecal immunochemical tests for haemoglobin (FIT) are widely used in 
asymptomatic population screening for colorectal (bowel) cancer.  FIT are also used 
to assist with the assessment of patients presenting with lower abdominal symptoms. 
Quantitative FIT allow the generation of numerical estimates of faecal haemoglobin 
(f-Hb) concentrations. There is now great interest in “low” f-Hb concentrations in 
these clinical settings: in consequence, knowledge of the detection capability is very 
important for f-Hb concentration examinations.   There are a number of current 
problems associated with the reporting of low f-Hb concentrations and wide 
misunderstanding of the metrological aspects of examinations of f-Hb at low 
concentrations. These would be solved if the detectability characteristics of f-Hb 
concentration examinations, namely, the limit of blank (LoB), limit of detection (LoD) 
and limit of quantitation (LoQ), were generated, validated and used in reporting 
systems exactly as recommended in the EP17-A2 guideline of the Clinical 
Laboratory Standards Institute (CLSI). LoB and LoD are statistical concepts, but the 
LoQ depends on definition of analytical performance specifications (APS). In this 
Opinion Paper proposals for interim APS are made, based on the current state of the 
art achieved with examinations of faecal samples.  It is proposed that LoQ is 
determined at an examination imprecision of CV <10% using faecal samples 
naturally positive for Hb rather than faeces spiked with haemolysate.   Detailed 
proposals for reporting f-Hb data at low concentrations are also made. 
 
 
 
 
  
Introduction 
 
Quantitative faecal immunochemical tests for haemoglobin (FIT) allow the generation 
of numerical estimates of the faecal haemoglobin (f-Hb) concentration in the samples 
provided for examination.  FIT are currently used very widely as the best non-
invasive investigation in asymptomatic population screening for bowel cancer [1]. FIT 
are also becoming increasingly used to assist with the assessment of patients 
presenting in primary care with lower abdominal symptoms who might have 
significant bowel disease [2]. There is great interest in low f-Hb concentrations in 
both these clinical settings.  These low f-Hb concentrations approach the detection 
capabilities of the quantitative FIT systems currently available on the market. 
Moreover, the detection capabilities approach the currently used clinical f-Hb 
concentration decision limits. In consequence, an understanding of the detection 
capability is very important for f-Hb concentration examinations.   
 
Current problems 
 
Many recent publications give f-Hb concentrations in integers from zero upwards, as 
recently documented [3]; however, the detection capability of currently available FIT 
systems does not support this.   In addition, some report numerical data on f-Hb 
concentrations with significant figures after the decimal point, as in the recent 
comparison of nine quantitative FIT approaches by Gies et al [4]. Both of these 
strategies for reporting f-Hb concentrations seem inappropriate, because neither the 
examination imprecision achievable nor the detection capabilities of currently 
available FIT systems warrant them.  In part this might be due to the fact that some 
manufacturers and users of FIT still quote their f-Hb concentration data as ng Hb/ml 
buffer and authors probably recalculate, from the quoted mass of faeces collected 
and the volume of buffer in the specimen collection device, to units of µg Hb/g faeces 
[5]. All manufacturers, suppliers and users of FIT should use µg Hb/g faeces to aid 
universal comprehension and transferability of data across FIT systems, as 
recommended by the Expert Working Group on FIT for Screening, Colorectal Cancer 
Screening Committee, World Endoscopy Organization (EWG) [6]. 
 
As discussed in detail recently [7], an additional problem is that there is wide 
misunderstanding of the metrological aspects of examinations of f-Hb at low 
concentrations.  The terminology used in the literature from both manufacturers and 
suppliers of FIT systems is often incorrect and misleading, such as the wide use of 
the term “sensitivity”.  Moreover, many publications on the use of FIT also use 
inappropriate terms and, sometimes, the numerical data documented about the FIT 
system used are actually reported incorrectly [3]. For example, in the recent study of 
Grobbee et al [8], the examination performance characteristics as documented by 
the manufacturers are actually misquoted. In part, this is understandable given the 
diversity of current terms used for the lowest f-Hb concentration that can be 
determined. There are a number of conflicting guidelines and recommendations on 
detection capability of clinical measurements, including from professional bodies, 
and as such, understanding may be inhibited by the fact that many of the 
metrological and technical terms used to describe processes for evaluating methods 
vary in different sectors, both in their meaning and the way they are determined [9], 
which does not help clarity.  
 
A solution 
 
 
Now seems to be the right time for all involved in generation and application of f-Hb 
concentration data, namely, FIT system manufacturers and suppliers, academic 
researchers, research funding bodies, authors and reviewers of papers, reviews and 
materials in modern media, journal editors and professionals in laboratory medicine 
to all use a single vocabulary and set of approaches. This opinion paper expands on 
the proposed approaches published recently [7].  These strongly advocated the use 
of internationally accepted terminology for the detection capability of examinations 
used in laboratory medicine and the derivation and application of the relevant 
performance characteristics. 
 
Since quantitative estimates of f-Hb concentration are probably best determined in 
medical laboratories accredited to ISO 15189 [10], we propose that the 
recommendations promulgated by the Clinical and Laboratory Standards Institute 
(CLSI), supported by the International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) [11], should be applied.  
 
 
Terminology 
 
The recommended terms to describe the detection capability of FIT are limit of blank 
(LoB), limit of detection (LoD) and limit of quantitation (LoQ). The details of how 
these are correctly established by manufacturers and validated by users, if required, 
are documented in detail in CLSI EP17- A2, Evaluation of Detection Capability for 
Clinical Laboratory Measurement Procedures, 2nd Edition, 2012 [11]. Full examples 
of the correct methodology to determine these performance characteristics are 
comprehensively documented. In addition, an excellent simple guide is given in a 
document prepared by a well-known manufacturer in laboratory medicine: this is 
available on the Internet [12]. 
 
Limit of blank: The LoB is the highest measured result (or analytical signal) likely to 
be observed (typically at 95% certainty) for a sample containing no f-Hb (a blank 
sample). It is the highest result that could be observed when a blank sample is 
repeatedly analysed. LoB is determined by estimating the standard deviation (SD) of 
replicate analyses of sample containing no f-Hb (blanks). Because allegedly 
everyone has some blood in their faeces, even in very tiny concentrations, we 
advocate the use of replicate analysis of the buffer in the specimen collection 
devices of the FIT system be used to determine the LoB rather than faecal samples. 
 
Limit of detection: LoD is the lowest concentration at which f-Hb can be detected 
95% of the time. LoD is determined by first determining LoB and then performing 
studies involving generation of replicate analyses of a sample or samples of faeces 
containing a very low f-Hb concentration. Mathematically, LoD can be calculated as 
LoD = LoB + (1.645 × the analytical SD of samples with low f-Hb concentration): 
1.645 is used for 95% probability because this is the appropriate one-sided Z-score. 
Here, it would be best to use real faecal samples obtained from participants in 
screening or patients presenting with lower abdominal symptoms, which should be 
collected into the FIT system specimen collection devices.  Specimens collected into 
traditional faecal collection pots are unsuitable for the determination of LoD, since 
any f-Hb will have degraded [13, 14] and the faeces will contain a mixture of f-Hb 
and degradation products, some of which might react with the polyclonal antibodies 
usually used in FIT. In consequence, it would be the LoD of this heterogeneous 
mixture that would be being estimated and not the LoD for f-Hb per se. 
 
Limit of quantitation: LoQ is the lowest amount of f-Hb that can be reliably 
measured. Whereas LoB and LoD are determined using statistical approaches, 
definition of LoQ depends on the documentation of pre-defined examination 
acceptance criteria. Practically, LoQ is the lowest f-Hb concentration that can be 
determined when some predefined analytical performance specifications (APS) are 
satisfied. The APS should be established using an internationally accepted and well-
documented strategy. There are a number of methods for determining LoQ. Use of 
the “precision profile” in which imprecision is plotted versus the f-Hb concentration 
has many advantages, allowing users to set LoQ based upon their own objectively 
set APS if they wish to use different APS to those recommended by the 
manufacturer of the FIT system used, or the APS proposed here. 
 
Setting analytical performance specifications (APS) for LoQ 
 
Definition of what is acceptable examination performance, through the setting of 
objective APS, is necessary to document the LoQ.  APS are widely defined as: the 
examination performance characteristics that are required to facilitate optimal health 
care.  The setting of APS has been the subject of much research over the last 40 
years [15].  Recently, the European Federation of Clinical Chemistry and Laboratory 
Medicine (EFLM) published a consensus statement on defining APS [16].   
 
The consensus agreed three different models to set APS and the statement details 
their advantages and disadvantages 
. 
Model 1. Based on the effect of examination performance on clinical outcomes. 
EFLM state that this can be done, in principle, using different types of studies: direct 
outcome studies – investigating the impact of examination performance on clinical 
outcomes - and indirect outcome studies – investigating the impact of examination 
performance on clinical classifications or decisions. 
 
Model 2. Based on components of biological variation of the measurand 
The advantage of this model is that it can be applied to most measurands for which 
estimates of the components of biological variation are available. 
 
Model 3. Based on state-of-the-art 
EFLM state that this could relate to the highest level of examination performance 
technically achievable. Alternatively, it could be defined as the performance achieved 
by a certain percentage of laboratories.  
 
Clearly, the three models use very different principles. Moreover, it is evident that 
some models will be better suited for certain measurands than for others. A list has 
been made by EFLM allocating measurands to different models [17], but f-Hb is not 
included. In addition, it is important to note that APS generated using these models 
may not be able to be met with currently available methodology and technology.  
Thus, APS may be aspirational rather than operational. 
 
Assessing the use of these three models for examinations of f-Hb concentrations in 
turn, there are no studies on the effect of performance on clinical outcomes, although 
mathematical models such as those documented by Petersen [18] could be 
generated using the consequences of performance on the distributions of f-Hb 
concentrations and, thereby, on clinical outcomes. There are no data on the biological 
variation of f-Hb concentrations, although estimates could be generated from the data 
collected on f-Hb concentrations in screening programmes that use two or more samples, in 
which the asymptomatic population could be regarded as apparently healthy [19], or studies 
done as that recently documented for faecal calprotectin [20]. However, the variation 
involved in sample collection, transport and handling (pre-examination variation) would likely 
have impact on the estimates generated. Thus, at this time, it seems that interim APS 
will have to be based upon the state of the art.  
 
The state of the art of faecal haemoglobin concentration examinations 
 
Unfortunately, very few publications actually follow the EWG guidelines on standards 
for FIT evaluation reporting guidelines, namely the FITTER guidelines [21,22]. 
Consequently, there is a paucity of data on examination performance characteristics 
in the peer-reviewed literature. Some data are available on examination performance 
attained, such as those documented in a comparative evaluation of four FIT systems 
[23]: these were generated using dilutions of a haemolysate of venous blood and 
thus do not represent those attained with real faecal samples and, in addition, the 
nomenclature used did not follow the CLSI recommendations. Further data are 
documented in a study on strategies to conduct evaluations of FIT [24], but again 
these were obtained using artificial biological samples (ABS), namely dilutions of a 
haemolysate of venous blood and reconstituted lyophilised third-party quality control 
materials Such quality control materials, provided by the manufacturers of FIT 
systems, have also been used to monitor the quality of f-Hb concentration 
examinations during a few of the studies on the use of FIT in the assessment of 
symptomatic patients [25-27].  None of these data use replicate analysis of faecal 
samples provided by participants or patients and are, therefore, likely to 
underestimate the examination imprecision attained. However, preliminary work from 
the laboratory of one of the authors (SCB) has used such faecal samples and 
created imprecision profiles. Taking all of the published data on examination 
imprecision into account, we recommend an interim APS for examination 
reproducibility of CV <10%. 
 
The guidelines on setting APS for LoQ suggest that these should be defined for bias. 
It is not considered that this can be done objectively at this time. As discussed 
earlier, the available FIT systems use polyclonal antibodies which react, not only with 
intact haemoglobin, but also early degradation products. Thus, the measurand is not 
identical across FIT systems. However, the Working Group on FIT of the Scientific 
Division of the IFCC (IFCC SD WG-FIT) is progressing the attainment of traceability 
of results of f-Hb concentration examinations to higher metrological materials and 
methods, with the aim of enhancing comparability across FIT systems [28] This will 
allow bias to be minimised and, in consequence, the APS for measurement 
uncertainty is also <10%. 
 
 
 
Proposals for reporting f-Hb data at low concentrations 
 
 
• Proposal 1:  f-Hb concentrations should not be reported to more significant 
figures than whole integers. 
 
• Proposal 2:  f-Hb concentrations less than the LoD should be termed “not 
detected” or “undetectable”. 
 
• Proposal 3: manufacturers should make precision profiles available to all 
users and detail their derivation. 
 
• Proposal 4: For academic use: f-Hb concentrations greater than the LoD 
could advantageously be documented, but it should be ensured that the 
correct LoD, as recorded by the manufacturer or supplier of the FIT system, is 
clearly detailed in all publications. Alternatively, if the laboratory generates the 
LoD from evaluation studies done in situ, detail of these need to be 
documented. 
 
• Proposal 5: Such academic reports should follow the FITTER guidelines 
[21,22] and inform on examination performance characteristics achieved, 
particularly at or near the LoD.  
 
• Proposal 6: For routine clinical use: numerical f-Hb concentrations should be 
reported only when greater than the LoQ, defined by the manufacturer 
according to CLSI EP17-A2 [11] and validated by the laboratory if required for 
accreditation purposes: f-Hb concentrations less than the LoQ (x) should be 
reported as < x µg Hb/g faeces. 
 
• Proposal 7: If a more sophisticated reporting system is required, one 
suggested option is [11,12]: report as  
 f-Hb concentration <  LoD = not detected    
 f-Hb concentration LoD < result < LoQ = f-Hb detected 
 f-Hb concentration ≥ LoQ = report the found f-Hb concentration  
 
• If LoD < result < LoQ, more sophisticated users of results might appreciate a 
report such as f-Hb = x µg Hb/g faeces with a comment such as “interpret this 
result with caution due to higher examination imprecision” or similar.  Further 
more complex options are detailed in CLSI EP17-A2 [11]. 
 
• Proposal 8: Efforts should be made to communicate the correct interpretation 
of reports of f-Hb concentration examination results to users and efforts 
should be made to encourage professionals in laboratory medicine to become 
involved with the other health care professionals involved in all uses of FIT 
[29]. 
 
Further requirements 
 
Quality management techniques should be in place to monitor examination 
performance, including use of internal quality control materials, incorporating third-
party controls, at appropriately low f-Hb concentrations. External quality assessment 
schemes (EQAS) are also urgently required. An interesting dilemma for the providers 
of EQAS for f-Hb concentrations is to decide whether mock faecal matrices with 
added haemoglobin should be circulated with the users having to sample into the 
appropriate specimen collection devices used by them: however, such EQAS would 
be assessing pre-examination variation as well as examination variation. 
Interestingly, a very recent paper describes the development of a ready to use 
artificial faeces containing Hb and glycerol as an internal standard: it was concluded 
that the in-house performance characteristics suggested that this artificial faeces 
was acceptable as an EQAS material for FIT [30]. Circulation of simple lyophilised, 
or liquid stable, materials containing human haemoglobin would assess only the 
examination variation. Data from both types of EQAS would be of interest: few exist 
at present but the IFCC SD WG-FIT is planning to collate and make available a list of 
available EQAS for f-Hb concentration examinations.  
 
Quality management procedures should be in place to ensure consistency of 
performance at low f-Hb concentrations when lots of reagents are changed with pre-
set criteria for acceptance or rejection of lots: these have been termed acceptance 
quality checks [31]. 
  
Conclusions 
 
The detectability characteristics of faecal haemoglobin concentration examinations 
should be generated, validated and used in reporting systems exactly as 
recommended in CLSI EP17-A2 [11]. Proposals for application of the detectability 
characteristics of LoD and LoQ are made in this Opinion Paper, along with the 
necessary definition of the APS required for documentation of LoQ. 
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